Literature DB >> 15917310

BRCA1 and BRCA2 as ovarian cancer susceptibility genes.

Heidi M Sowter1, Alan Ashworth.   

Abstract

Individuals carrying germline mutations in one allele of the BRCA1 or BRCA2 genes are at significantly increased risk of developing cancer. Although the increased risk of breast cancer is often highlighted, cancer at several other sites is also considerably more common in these individuals. Here, we discuss existing knowledge of the role of BRCA1 and BRCA2 mutation in pre-disposition to ovarian cancer. The risk of an individual with a mutation developing cancer of the ovary appears to be influenced by the position of the mutation within the BRCA gene, the presence of allelic variants of modifying genes and the hormonal exposure of the carrier. Once cancer has developed, the pathology and clinical behaviour of BRCA-associated tumours is distinct from sporadic cases. Comparison of the pathogenesis of breast and ovarian cancers caused by BRCA mutation provides insight into the function of BRCA proteins as tumour suppressors in different cellular environments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917310     DOI: 10.1093/carcin/bgi136

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  "Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation.

Authors:  Regina Kenen; Audrey Ardern-Jones; Rosalind Eeles
Journal:  J Genet Couns       Date:  2006-06       Impact factor: 2.537

2.  Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives.

Authors:  Audrey Ardern-Jones; Regina Kenen; Elly Lynch; Rebecca Doherty; Rosalind Eeles
Journal:  Hered Cancer Clin Pract       Date:  2010-01-12       Impact factor: 2.857

3.  BRCA1 alterations are associated with endometriosis, but BRCA2 alterations show no detectable endometriosis risk: a study in Indian population.

Authors:  Suresh Govatati; Kiran Challa; Sunita B Reddy; Kayathi Pramod; Mamata Deenadayal; Baidyanath Chakravarty; Sisinthy Shivaji; Manjula Bhanoori
Journal:  J Assist Reprod Genet       Date:  2014-11-08       Impact factor: 3.412

4.  Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result.

Authors:  Regina Kenen; Audrey Ardern-Jones; Elly Lynch; Rosalind Eeles
Journal:  Genet Test Mol Biomarkers       Date:  2011-01-22

Review 5.  Making the best of PARP inhibitors in ovarian cancer.

Authors:  Susana Banerjee; Stan B Kaye; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

6.  RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.

Authors:  Jessica Clague; Greg Wilhoite; Aaron Adamson; Adam Bailis; Jeffrey N Weitzel; Susan L Neuhausen
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

7.  Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?

Authors:  Guo-Yan Liu; Wei Zhang
Journal:  Chin J Cancer       Date:  2011-12-16

8.  Integrative network analysis of TCGA data for ovarian cancer.

Authors:  Qingyang Zhang; Joanna E Burdette; Ji-Ping Wang
Journal:  BMC Syst Biol       Date:  2014-12-31

9.  CHEK2 1100 delC mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Daria N Ponomariova; Natalia Yu Sherina; Natalia Yu Ogorodnikova; Denis A Logvinov; Natalia V Porhanova; Oksana S Lobeiko; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Suspitsin; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

10.  Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.

Authors:  Yongliang Yang; Pavel Pospisil; Lakshmanan K Iyer; S James Adelstein; Amin I Kassis
Journal:  PLoS One       Date:  2008-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.